Angiogenesis is the process of the formation of new blood vessels from those that already exist. There are multiple factors that work as angiogenic stimulants, including FGF, TGF-beta, and VEGF, which results in the MAPK pathway to initiate the growth process. MMPs are also important in angiogenesis, as they degrade the extracellular matrix and allow for the new blood vessels to grow from this location. Sprouting angiogenesis is the most common form of angiogenesis, where new cells grow off of a blood vessel and fuse together to form a shared lumen. The sprouts migrate toward the angiogenic stimulus and are connected through the use of integrins to form entirely new vessels. Angiogenesis is an important function in the oxygenation of tissues, and can help in various functions including wound healing and the treatment of vascular diseases such as heart disease, high blood pressure, and diabetes. An abnormal rate of angiogenesis, however, can cause many problems including the proliferation of cancerous tumors, diabetic ulcers, and cardiovascular diseases. Many scientists have studied factors of angiogenesis, and treatments have been created that involve either the inhibition or activation of blood vessel growth.
Sprouting Angiogenesis Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Sprouting Angiogenesis below!
For more information on how to use Laverne, please read the How to Guide.
We have 3017 products for the study of the Sprouting Angiogenesis Pathway that can be applied to Western Blot, Flow Cytometry, Chromatin Immunoprecipitation, Immunohistochemistry, Immunocytochemistry/Immunofluorescence from our catalog of antibodies and ELISA kits.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.